Interaction of xenobiotics on the glucose-transport system and the Na⁺/K⁺-ATPase of human skin fibroblastsCASCORBI, I; FORET, M.Ecotoxicology and environmental safety (Print). 1991, Vol 21, Num 1, pp 38-46, issn 0147-6513, 9 p.Article

Pitfalls in N-acetyltransferase 2 genotypingCASCORBI, I; ROOTS, I.Pharmacogenetics (London). 1999, Vol 9, Num 1, pp 123-127, issn 0960-314XArticle

Correlation between the lipophilicity of substituted phenols and their inhibition of the Na⁺/K⁺-ATPase of Chinese hamster ovary cellsCASCORBI, I; AHLERS, J.Toxicology (Amsterdam). 1989, Vol 58, Num 2, pp 197-210, issn 0300-483X, 14 p.Article

A C4887A polymorphism in exon 7 of human CYP1A1 : Population frequency, mutation linkages, and impact on lung cancer susceptibilityCASCORBI, I; BROCKMÖLLER, J; ROOTS, I et al.Cancer research (Baltimore). 1996, Vol 56, Num 21, pp 4965-4969, issn 0008-5472Article

Molecular-epidemiological aspects of carcinogenesis: the role of xenobiotic metabolizing enzymesCASCORBI, I; BROCKMÖLLER, J; ROOTS, I et al.International journal of clinical pharmacology and therapeutics. 2002, Vol 40, Num 12, pp 562-563, issn 0946-1965, 2 p.Conference Paper

Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer riskBROCKMÖLLER, J; CASCORBI, I; KERB, R et al.Cancer research (Baltimore). 1996, Vol 56, Num 17, pp 3915-3925, issn 0008-5472Article

Polymorphisms in xenobiotic conjugation and disease predispositionBROCKMÖLLER, J; CASCORBI, I; KERB, R et al.Toxicology letters. 1998, Vol 102-03, pp 173-183, issn 0378-4274Conference Paper

CYP1A1 mutations 4887A, 4889G, 5639C and 6235C in the Polish population and their allelic linkage, determined by peptide nucleic acid-mediated PCR clampingMROZIKIEWICZ, P. M; CASCORBI, I; BROCKMÖLLER, J et al.Pharmacogenetics (London). 1997, Vol 7, Num 4, pp 303-307, issn 0960-314XArticle

Arylamine N-acetyltransferase (NAT2) genotypes in a Turkish populationSÜKRÜ AYNACIOGLU, A; CASCORBI, I; MROZIKIEWICZ, P. M et al.Pharmacogenetics (London). 1997, Vol 7, Num 4, pp 327-331, issn 0960-314XArticle

Co-trimoxazole-induced liver and renal failure : Case reportWINDECKER, R; STEFFEN, J; CASCORBI, I et al.European journal of clinical pharmacology. 2000, Vol 56, Num 2, pp 191-193, issn 0031-6970Article

NAT2*12A (803A→G) codes for rapid arylamine N-acetylation in humansCASCORBI, I; BROCKMÖLLER, J; BAUER, S et al.Pharmacogenetics (London). 1996, Vol 6, Num 3, pp 257-259, issn 0960-314XArticle

Association of arylamine N-acetyltransferases NAT1 and NAT2 genotypes to laryngeal cancer riskHENNING, S; CASCORBI, I; MÜNCHOW, B et al.Pharmacogenetics (London). 1999, Vol 9, Num 1, pp 103-111, issn 0960-314XArticle

Elimination Half-Life of Anti-Müllerian HormoneGRIESINGER, G; DAFOPOULOS, K; BUENDGEN, N et al.The Journal of clinical endocrinology and metabolism. 2012, Vol 97, Num 6, pp 2160-2163, issn 0021-972X, 4 p.Article

Influence of CYP3A4, CYP3A5, and ABCB1 Genotype and Expression on Budesonide Pharmacokinetics : A Possible Role of Intestinal CYP3A4 ExpressionUFER, M; DILGER, K; CASCORBI, I et al.Clinical pharmacology and therapeutics. 2008, Vol 84, Num 1, pp 43-46, issn 0009-9236, 4 p.Article

Co-expression of human cytochrome P4501A1 (CYP1A1) variants and human NADPH-cytochrome P450 reductase in the baculovirus/insect cell systemSCHWARZ, D; KISSELEV, P; HONECK, H et al.Xenobiotica (London. Print). 2001, Vol 31, Num 6, pp 345-356, issn 0049-8254Article

Allelic variants of human cytochrome P450 1A1 (CYP1a1) : effect of T461N and I462V substitutions on steroid hydroxylase specificitySCHWARZ, D; KISSELEV, P; SCHUNCK, W.-H et al.Pharmacogenetics (London). 2000, Vol 10, Num 6, pp 519-530, issn 0960-314XArticle

Correlation between genotype and phenotype of the human arylamine N-acetyltransferase type 1 (NAT1)BRUHN, C; BROCKMÖLLER, J; CASCORBI, I et al.Biochemical pharmacology. 1999, Vol 58, Num 11, pp 1759-1764, issn 0006-2952Article

Further evidence of human leukocyte antigen-encoded susceptibility to clozapine-induced agranulocytosis independent of ancestryDETTLING, M; SCHAUB, R. T; MUELLER-OERLINGHAUSEN, B et al.Pharmacogenetics (London). 2001, Vol 11, Num 2, pp 135-141, issn 0960-314XArticle

A1166C polymorphism of the angiotensin II type 1 receptor gene and risk of adverse events after coronary catheter interventionsSTANGL, K; CASCORBI, I; STANGL, V et al.The American heart journal. 2000, Vol 140, Num 1, pp 170-175, issn 0002-8703Conference Paper

High CA repeat numbers in intron 13 of the endothelial nitric oxide synthase gene and increased risk of coronary artery diseaseSTANGL, K; CASCORBI, I; ROOTS, I et al.Pharmacogenetics (London). 2000, Vol 10, Num 2, pp 133-140, issn 0960-314XArticle

Genetic determinants of drug-induced agranulocytosis : Potential risk of olanzapine?DETTLING, M; CASCORBI, I; HELLWEG, R et al.Pharmacopsychiatry. 1999, Vol 32, Num 3, pp 110-112, issn 0176-3679Article

A1/A2 polymorphism of glycoprotein IIIa and association with excess procedural risk for coronary catheter interventions : a case-controlled studyLAULE, M; CASCORBI, I; STANGL, V et al.Lancet (British edition). 1999, Vol 353, Num 9154, pp 708-712, issn 0140-6736Article

Identification and Characterization of a Defective CYP3A4 Genotype in a KidneyTransplant Patient With Severely Diminished Tacrolimus ClearanceWERK, A. N; LEFELDT, S; HEEMANN, U et al.Clinical pharmacology and therapeutics. 2014, Vol 95, Num 4, pp 416-422, issn 0009-9236, 7 p.Article

No benefit of 3,4-diaminopyridine in essential tremor : A placebo-controlled crossover studyLORENZ, D; HAGEN, K; UFER, M et al.Neurology. 2006, Vol 66, Num 11, pp 1753-1755, issn 0028-3878, 3 p.Article

Substantially reduced risk of cancer of the aerodigestive tract in subjects with variant -463A of the myeloperoxidase geneCASCORBI, I; HENNING, S; BROCKMÖLLER, J et al.Cancer research (Baltimore). 2000, Vol 60, Num 3, pp 644-649, issn 0008-5472Article